145 related articles for article (PubMed ID: 7483805)
1. Immunogenicity of the yeast recombinant p17/p24:Ty virus-like particles (p24-VLP) in healthy volunteers.
Weber J; Cheinsong-Popov R; Callow D; Adams S; Patou G; Hodgkin K; Martin S; Gotch F; Kingsman A
Vaccine; 1995 Jun; 13(9):831-4. PubMed ID: 7483805
[TBL] [Abstract][Full Text] [Related]
2. Immunization of human HIV-seronegative volunteers with recombinant p17/p24:Ty virus-like particles elicits HIV-1 p24-specific cellular and humoral immune responses.
Martin SJ; Vyakarnam A; Cheingsong-Popov R; Callow D; Jones KL; Senior JM; Adams SE; Kingsman AJ; Matear P; Gotch FM
AIDS; 1993 Oct; 7(10):1315-23. PubMed ID: 8267904
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens.
Kmieciak D; Bolesta E; Naito T; Gzyl J; Kaneko Y; Kozbor D
J Hum Virol; 2001; 4(6):306-16. PubMed ID: 12082397
[TBL] [Abstract][Full Text] [Related]
4. Gag-specific immune responses after immunization with p17/p24:Ty virus-like particles in HIV type 1-seropositive individuals.
Klein MR; Veenstra J; Holwerda AM; Roos MT; Gow I; Patou G; Coutinho RA; De Wolf F; Miedema F
AIDS Res Hum Retroviruses; 1997 Mar; 13(5):393-9. PubMed ID: 9075480
[TBL] [Abstract][Full Text] [Related]
5. A pilot phase II study of the safety and immunogenicity of HIV p17/p24:VLP (p24-VLP) in asymptomatic HIV seropositive subjects.
Peters BS; Cheingsong-Popov R; Callow D; Foxall R; Patou G; Hodgkin K; Weber JN
J Infect; 1997 Nov; 35(3):231-5. PubMed ID: 9459393
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up: no effect of therapeutic vaccination with HIV-1 p17/p24:Ty virus-like particles on HIV-1 disease progression.
Lindenburg CE; Stolte I; Langendam MW; Miedema F; Williams IG; Colebunders R; Weber JN; Fisher M; Coutinho RA
Vaccine; 2002 May; 20(17-18):2343-7. PubMed ID: 12009290
[TBL] [Abstract][Full Text] [Related]
7. Decline in CTL and antibody responses to HIV-1 p17 and p24 antigens in HIV-1-infected hemophiliacs irrespective of disease progression. A 5-year follow-up study.
O'Toole CM; Lowdell MW; Chargelegue D; Colvin BT
AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1361-8. PubMed ID: 1281655
[TBL] [Abstract][Full Text] [Related]
8. Immunization with recombinant p17/p24:Ty virus-like particles in human immunodeficiency virus-infected persons.
Veenstra J; Williams IG; Colebunders R; Dorrell L; Tchamouroff SE; Patou G; Lange JM; Weller IV; Goeman J; Uthayakumar S; Gow IR; Weber JN; Coutinho RA
J Infect Dis; 1996 Oct; 174(4):862-6. PubMed ID: 8843231
[TBL] [Abstract][Full Text] [Related]
9. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
Kang CY; Luo L; Wainberg MA; Li Y
Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
[TBL] [Abstract][Full Text] [Related]
10. The affinity of IgG antibodies to gag p24 and p17 in HIV-1-infected patients correlates with disease progression.
Chargelegue D; Stanley CM; O'Toole CM; Colvin BT; Steward MW
Clin Exp Immunol; 1995 Feb; 99(2):175-81. PubMed ID: 7851008
[TBL] [Abstract][Full Text] [Related]
11. Prevalence and persistence of antibody titers to recombinant HIV-1 core and matrix proteins in HIV-1 infection.
Janvier B; Mallet F; Cheynet V; Dalbon P; Vernet G; Besnier JM; Choutet P; Goudeau A; Mandrand B; Barin F
J Acquir Immune Defic Syndr (1988); 1993 Aug; 6(8):898-903. PubMed ID: 8315575
[TBL] [Abstract][Full Text] [Related]
12. Limiting dilution analysis of cytotoxic T lymphocytes to human immunodeficiency virus gag antigens in infected persons: in vitro quantitation of effector cell populations with p17 and p24 specificities.
Koup RA; Pikora CA; Luzuriaga K; Brettler DB; Day ES; Mazzara GP; Sullivan JL
J Exp Med; 1991 Dec; 174(6):1593-600. PubMed ID: 1744586
[TBL] [Abstract][Full Text] [Related]
13. Antibody recognition of synthetic peptides mimicking immunodominant regions of HIV-1 p24 and p17 proteins.
Lottersberger J; Salvetti JL; Beltramini LM; Tonarelli G
Rev Argent Microbiol; 2004; 36(4):151-7. PubMed ID: 15786866
[TBL] [Abstract][Full Text] [Related]
14. Polyfunctional CD4(+) T cell responses in HIV-1-infected viral controllers compared with those in healthy recipients of an adjuvanted polyprotein HIV-1 vaccine.
Van Braeckel E; Desombere I; Clement F; Vandekerckhove L; Verhofstede C; Vogelaers D; Leroux-Roels G
Vaccine; 2013 Aug; 31(36):3739-46. PubMed ID: 23707169
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of a candidate therapeutic vaccine, p24 virus-like particle, combined with zidovudine, in asymptomatic subjects. Community HIV Research Network Investigators.
Kelleher AD; Roggensack M; Jaramillo AB; Smith DE; Walker A; Gow I; McMurchie M; Harris J; Patou G; Cooper DA
AIDS; 1998 Jan; 12(2):175-82. PubMed ID: 9468366
[TBL] [Abstract][Full Text] [Related]
16. A novel method for the purification of HIV-1 p24 protein from hybrid Ty virus-like particles (Ty-VLPs).
Gilmour JE; Senior JM; Burns NR; Esnouf MP; Gull K; Kingsman SM; Kingsman AJ; Adams SE
AIDS; 1989 Nov; 3(11):717-23. PubMed ID: 2559750
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 Gag variants.
Klenerman P; Rowland-Jones S; McAdam S; Edwards J; Daenke S; Lalloo D; Köppe B; Rosenberg W; Boyd D; Edwards A
Nature; 1994 Jun; 369(6479):403-7. PubMed ID: 7515165
[TBL] [Abstract][Full Text] [Related]
18. Optimal conditions of immune complex transfer enzyme immunoassays for antibody IgGs to HIV-1 using recombinant p17, p24, and reverse transcriptase as antigens.
Hashida S; Ishikawa S; Hashinaka K; Nishikata I; Oka S; Shimada K; Saito A; Takamizawa A; Shinagawa H; Ishikawa E
J Clin Lab Anal; 1998; 12(2):98-107. PubMed ID: 9524294
[TBL] [Abstract][Full Text] [Related]
19. Differential maturation of avidity of IgG antibodies to gp41, p24 and p17 following infection with HIV-1.
Thomas HI; Wilson S; O'Toole CM; Lister CM; Saeed AM; Watkins RP; Morgan-Capner P
Clin Exp Immunol; 1996 Feb; 103(2):185-91. PubMed ID: 8565298
[TBL] [Abstract][Full Text] [Related]
20. A longitudinal study of the IgG antibody response to HIV-1 p17 gag protein in HIV-1+ patients with haemophilia: titre and avidity.
Chargelegue D; O'Toole CM; Colvin BT
Clin Exp Immunol; 1993 Sep; 93(3):331-6. PubMed ID: 8370162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
